Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0493 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| MK0493 | DRUG | - |
Inclusion Criteria: * Patient is between 21 and 65 years of age Exclusion Criteria: * HIV positive as determined by medical history * Patient is pregnant, lactating or plans to become pregnant * Patient has undergone surgical treatment for obesity * Patient has undergone a surgical procedure with...
Top 20 of 32 competitors
MK0493 is an investigational small molecule being developed by Merck & Company, Inc. for the treatment of obesity. It is in Phase 2 clinical development, and two completed trials have studied its safety, efficacy, and tolerability in obese patients. MK0493 is not approved and remains under clinical investigation.
MK0493 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. The company has sponsored Phase 2 clinical trials of MK0493 in obesity, and the drug is currently in clinical development.
MK0493 is in Phase 2 clinical development for obesity. Two Phase 2 trials have been completed, with a total enrollment of 173 participants in one of the studies. MK0493 is investigational and has not been approved by regulatory authorities.
MK0493 has been studied in two completed Phase 2 clinical trials: NCT00482196, which evaluated different levels of MK0493 for safety, efficacy, and tolerability in obese patients, and NCT00482638, which studied the safety, tolerability, and efficacy of MK0493 in obese patients. Both trials enrolled adults aged 21 years and older.
MK0493 is not FDA approved. It is an investigational drug in Phase 2 clinical development for obesity. Two clinical trials have been completed, but the drug has not received regulatory approval and remains under investigation for safety and efficacy.